“South Africa’s CSIR, backed by the EU’s Global Gateway project and the German Development Bank (KfW), is establishing a Southern African Biomanufacturing Training Hub to build specialized skills in vaccine and pharmaceutical production. The hub will train up to 400 candidates annually, positioning South Africa as a continental leader in biotechnology and health security.”
On September 1, 2026, South Africa’s Council for Scientific and Industrial Research (CSIR) announced a landmark initiative: the creation of the Southern African Biomanufacturing Training Hub, funded through a grant from the European Union and facilitated by the German Development Bank (KfW). This development represents a major step toward strengthening Africa’s biotechnology ecosystem, particularly in vaccine and pharmaceutical manufacturing.
Background and Context
The COVID-19 pandemic exposed Africa’s vulnerability to global supply chain disruptions in vaccines and medicines. While South Africa has made strides in local vaccine production, the continent still imports the majority of its pharmaceuticals. The EU’s Global Gateway flagship project aims to address this imbalance by investing in biomanufacturing capacity, skills development, and health technology access.
Objectives of the Training Hub
The hub will:
- Train 400 candidates per year in biomanufacturing.
- Offer structured programs from foundational to advanced levels.
- Focus on bioprocess development, vaccine production, quality control, and large-scale operations.
- Strengthen health security by ensuring Africa can produce its own vaccines and therapeutics.
Strategic Importance
- Health Security: Reduces reliance on imports and external supply chains.
- Industrial Competitiveness: Positions South Africa as a biotechnology hub for Africa.
- Job Creation: Expands opportunities in pharmaceutical and biopharmaceutical industries.
- Innovation Ecosystem: Encourages collaboration between academia, government, and industry.
Partnerships and Collaboration
The CSIR will manage the hub in partnership with national and international institutions, ensuring global best practices are integrated. The EU’s involvement underscores Europe’s commitment to Africa’s health resilience, while KfW’s role highlights Germany’s investment in sustainable development.
Training Infrastructure
The funding will upgrade CSIR’s existing facilities, enabling hands-on training with modern equipment. This infrastructure will support:
- Pilot-scale biomanufacturing operations.
- Good Manufacturing Practices (GMP) training.
- Specialized vaccine production modules.
Economic and Social Impact
The hub is expected to:
- Create high-skilled jobs in biotechnology.
- Support local pharmaceutical companies.
- Enhance Africa’s bargaining power in global health negotiations.
- Contribute to regional economic growth through industrial development.
Expert Perspectives
Dr. Santosh Ramchuran, CSIR’s chief researcher, emphasized that the program is designed to create a clear pathway from foundational skills to specialist expertise. CSIR CEO Dr. Thulani Dlamini added that strengthening skills across the biomanufacturing value chain will contribute to a resilient African health and innovation ecosystem.
Challenges Ahead
Despite the promise, challenges remain:
- Sustained investment is required to maintain infrastructure.
- Regulatory frameworks must be harmonized across African countries.
- Collaboration between government, academia, and industry must be deepened.
Conclusion
The Southern African Biomanufacturing Training Hub represents a transformative milestone for South Africa and the continent. By investing in skills, infrastructure, and partnerships, the initiative will not only strengthen Africa’s health security but also catalyze industrial growth and innovation.
